No new digest content identified.
National Health Commission of the People’s Republic of China [to 27 Feb 2021]
Feb 27: Daily briefing on novel coronavirus cases in China
On Feb 26, 31 provincial-level regions and the Xinjiang Production and Construction Corps on the Chinese mainland reported 10 new cases of confirmed infections.
Children aged 3-17 to be eligible for Sinopharm vaccine
Chinese drugmaker Sinopharm said people aged 3 to 17 years old who are currently not included in the COVID-19 vaccine rollout will soon become eligible to receive inoculation…
Results from clinical trials involving the younger population have shown “no obvious differences” from trial data concerning those aged 18 to 59 years old, Liu said during an interview with China Central Television on Sunday.
“So we believe those aged 3 to 17 will soon be able to use the vaccines,” he said…
National Medical Products Administration – PRC [to 27 Feb 2021]
NMPA grants conditional approval to CanSino’s recombinant COVID-19 vaccine
The National Medical Products Administration (NMPA) conditionally approved the registration application of the recombinant COVID-19 vaccine (adenovirus type-5-vectored vaccine) developed by CanSino Biologics on Feb 25.
NMPA conditionally approves COVID-19 vaccine developed by Sinopharm’s Wuhan institute
The National Medical Products Administration (NMPA) conditionally approved the registration application of the inactivated COVID-19 vaccine (Vero cell) developed by the Wuhan Institute of Biological Products administered by Sinopharm on Feb 25.